구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | vinorelbine tartrate (vinorelbine tartrate) Jiangsu Tasly Diyi Pharmaceutical …·Adult Lymphocyte Depletion Hodgkin… 91 trials |
|---|---|
Overview Program | vinorelbine tartrate |
Overview Company | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. |
Overview Modality | ADC |
Overview Target | Adult Lymphocyte Depletion Hodgkin Lymph |
Overview Indication | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | HER2)-positive |
PK/PD Species | Mouse, Rat, cell line. |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse, Rat, cell line. |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia was uncommon) and gastrointestinal toxicities (nausea, vomiting, abdominal pain |
Toxicology CRS | 88.9% |
Clinical Safety signal | thrombocytopenia was uncommon) and gastrointestinal toxicities (nausea, vomiting, abdominal pain |
Clinical Selected reported efficacy | ORR 52% |
Clinical Reported ORR | 52% |
Clinical Reported PFS | 2.8 |
Clinical Reported OS | 11.7 |
Clinical Result source | ClinicalTrials.gov NCT03257267 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03257267 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | vinorelbine tartrate (vinorelbine tartrate) Jiangsu Tasly Diyi Pharmaceutical …·Adult Lymphocyte Depletion Hodgkin… 91 trials |
|---|---|
Overview Program | vinorelbine tartrate |
Overview Company | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. |
Overview Modality | ADC |
Overview Target | Adult Lymphocyte Depletion Hodgkin Lymph |
Overview Indication | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | HER2)-positive |
PK/PD Species | Mouse, Rat, cell line. |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | Biodistribution |
Toxicology Species | Mouse, Rat, cell line. |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | thrombocytopenia was uncommon) and gastrointestinal toxicities (nausea, vomiting, abdominal pain |
Toxicology CRS | 88.9% |
Clinical Safety signal | thrombocytopenia was uncommon) and gastrointestinal toxicities (nausea, vomiting, abdominal pain |
Clinical Selected reported efficacy | ORR 52% |
Clinical Reported ORR | 52% |
Clinical Reported PFS | 2.8 |
Clinical Reported OS | 11.7 |
Clinical Result source | ClinicalTrials.gov NCT03257267 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03257267 |
추천 비교
추천 비교